Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

Abstract

AbstractThe addition of cladribine, or sorafenib to standard chemotherapy have each demonstrated improved survival in patients with newly‐diagnosed acute myeloid leukemia (AML). We studied the combination of cladribine, idarubicin, and intermediate‐dose cytarabine (CLIA) in patients ≤65 years of age with newly diagnosed AML, fit to receive intensive therapy. Cladribine (5 mg/m2) IV was administered on days (D)1–5, cytarabine (1 g/m2) on D1‐5, and idarubicin (10 mg/m2) on D1‐3. Sorafenib was added to the CLIA backbone for patients with FLT3‐ITD mutated AML. 80 patients were enrolled: 65 with newly diagnosed AML and 15 with AML arising from previously treated MDS (ts‐AML). The median age was 55 years (range, 21–65). CR + CRi was 83% (54/65) and 27% in the untreated and ts‐AML cohorts, respectively; 74% and 75% of responding patients, respectively, had undetectable measurable residual disease (MRD). Among patients with FLT3‐ITD mutated AML receiving CLIA+sorafenib, the CR + CRi rate was 95%, with 81% negative for MRD. With a median follow‐up of 76 months, the 2‐ and 4‐year OS of 57% and 50% compared to 20%, and 13% for ts‐AML, respectively. Patients treated with CLIA+sorafenib had 2‐ and 5‐year OS rates of 63% and 59%, respectively. The most common Grade ≥3 adverse events were infection/fever, elevated bilirubin, rash, and nausea. CLIA was safe and effective in young, fit patients with newly diagnosed AML with inferior outcomes among patients with ts‐AML. The addition of sorafenib to CLIA in FLT3‐ITD mutated AML resulted in high rates of durable remission and excellent long‐term survival.